Patent · US Active

Compounds, compositions, and methods

US9932325B2 · kind B2 · utility

11Cited by
5References
30Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 25, 2017
Grant dateApr 3, 2018
Priority date—
Expiry dateOct 25, 2037

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07B2200/05
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.